Vertex Pharmaceuticals Incorporated to acquire Crinetics Pharmaceuticals, Inc.

Vertex Pharmaceuticals Incorporated has agreed to acquire Crinetics Pharmaceuticals, Inc. in a going private transaction valued at $10 billion. The deal, announced on 6 July 2026, involves full cash consideration for all outstanding shares of the target company. This strategic move allows Vertex to fully integrate Crinetics’ pipeline and operations into its broader healthcare portfolio. Both entities are based in the United States, operating within the healthcare sector. The headline offer price reflects a significant premium over previous market valuations, signalling strong confidence in the combined entity’s future growth potential.

The transaction was completed on 1 September 2026, following the satisfaction of all necessary closing conditions. Crinetics Pharmaceuticals will cease to be a publicly traded company and will operate as a wholly owned subsidiary of Vertex Pharmaceuticals. This acquisition consolidates Vertex’s position in rare disease treatments and expands its research capabilities. The integration process is expected to streamline development efforts and accelerate the commercialisation of key assets. Regulatory approvals were secured prior to completion, ensuring a smooth transition for all stakeholders involved in the deal.